Technical Analysis for RDHL - Redhill Biopharma Ltd.

Grade Last Price % Change Price Change
F 8.17 -0.85% -0.07
RDHL closed down 0.85 percent on Friday, November 1, 2024, on 23 percent of normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Down Down Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
180 Bearish Setup Bearish Swing Setup -0.85%
20 DMA Support Bullish -0.85%
Bollinger Band Squeeze Range Contraction -0.85%
Narrow Range Bar Range Contraction -0.85%
Crossed Above 20 DMA Bullish -2.04%
Bollinger Band Squeeze Range Contraction -2.04%
Narrow Range Bar Range Contraction -2.04%

   Recent Intraday Alerts

Alert Time
10 DMA Resistance about 21 hours ago
Fell Below 20 DMA about 21 hours ago
Possible NR7 about 21 hours ago
20 DMA Support about 23 hours ago
10 DMA Support about 23 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Redhill Biopharma Ltd. Description

RedHill Biopharma Ltd., a biopharmaceutical company, engages in the acquisition and development of patent-protected new formulations and combinations of existing drugs in advanced stages of development. The company's pipeline includes six clinical stage therapeutic candidates comprising RHB-101, a once daily controlled release patented formulation of Carvedilol for the treatment of hypertension, heart failure, and left ventricular dysfunction; RHB-102, a once daily controlled release oral formulation of Ondansetron for the prevention of nausea and vomiting for oncology-support treatments; and RHB-103, a proprietary oral fast dissolving thin film formulation of rizatriptan for the treatment of acute migraine headaches. Its pipeline also consists of RHB-104, a patented antibiotics drug for the treatment of inflammatory bowel disease focused on Crohn's disease patients; RHB-105, an antibiotics and proton pump inhibitor proprietary drug targeting helicobacter pylori infection; and RHB-106, a patented formulation in tablet form for the preparation and cleansing of the gastrointestinal tract. RedHill Biopharma Ltd. was founded in 2009 and is based in Tel Aviv, Israel.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Autoimmune Disease Gastrointestinal Hypertension Antibiotics Heart Failure Dysfunction Inflammatory Bowel Disease Gastroenterology Thin Film Abdominal Pain Crohn's Disease Headache Migraine Nausea Proton Bacteria Gastrointestinal Tract Migraine Headache Treatment Of Hypertension Treatment Of Inflammatory Bowel Disease Helicobacter Migraine Headaches

Is RDHL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2050.0
52 Week Low 7.34
Average Volume 47,547
200-Day Moving Average 225.84
50-Day Moving Average 8.89
20-Day Moving Average 8.21
10-Day Moving Average 8.21
Average True Range 1.93
RSI (14) 15.25
ADX 70.64
+DI 12.67
-DI 47.76
Chandelier Exit (Long, 3 ATRs) 3.20
Chandelier Exit (Short, 3 ATRs) 13.60
Upper Bollinger Bands 8.64
Lower Bollinger Band 7.78
Percent B (%b) 0.45
BandWidth 10.46
MACD Line -4.98
MACD Signal Line -7.18
MACD Histogram 2.1973
Fundamentals Value
Market Cap 242.67 Million
Num Shares 29.7 Million
EPS -8.00
Price-to-Earnings (P/E) Ratio -1.02
Price-to-Sales 0.48
Price-to-Book 4.98
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.55
Resistance 3 (R3) 8.55 8.42 8.48
Resistance 2 (R2) 8.42 8.33 8.42 8.46
Resistance 1 (R1) 8.30 8.27 8.24 8.30 8.44
Pivot Point 8.17 8.17 8.14 8.17 8.17
Support 1 (S1) 8.05 8.08 7.99 8.05 7.90
Support 2 (S2) 7.92 8.02 7.92 7.88
Support 3 (S3) 7.80 7.92 7.86
Support 4 (S4) 7.80